摘要 |
The invention relates to a pharmaceutical composition containing an effective quantity of angiotensin-(1-9) or derivatives thereof and at least one pharmaceutically acceptable carrier, excipient, stabilising agent, diluent and/or adjuvant. In addition, the invention relates to the use of the pharmaceutical composition and peptide angiotensin-(1-9), or peptides derived therefrom which are biological or chemical analogues, for the production of drugs that can be used to prevent, reverse, inhibit and/or reduce cardiovascular, pulmonary, cerebral or renal remodeling. The invention further relates to a method for preventing, reversing, inhibiting and/or reducing cardiovascular, pulmonary, cerebral or renal remodeling, consisting of raising the concentration of peptide angiotensin-(1-9) or peptides derived therefrom in the blood and/or tissues, using a pharmaceutical composition containing a vector expressing ECA2, the enzyme responsible for the endogenous production of angiotensin-(1-9). Said vectors correspond to adenoviruses, retroviruses, lentiviruses or adeno-associated viruses containing the gene that codes for ECA2. The invention can be used for the administration of angiotensin-(1-9) or derivatives thereof in oral form, in injectable form or by means of continuous pump infusion or to raise the levels of same in the body by means of treatment with: angiotensin-I-converting-enzyme inhibitors, angiotensin II (ARA II) receptor antagonists, Rho kinase inhibitors, antagonists of the calcium L-channels and/or diuretics. |
申请人 |
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE;UNIVERSIDAD DE CHILE;OCARANZA JERALDINO, MARIA PAZ;LAVANDERO GONZALEZ, SERGIO;JALIL MILAD, JORGE;CHIONG LA Y, MARIO |
发明人 |
OCARANZA JERALDINO, MARIA PAZ;LAVANDERO GONZALEZ, SERGIO;JALIL MILAD, JORGE;CHIONG LA Y, MARIO |